Ptc Therapeutics (PTCT) Gross Profit (2016 - 2026)

Ptc Therapeutics' Gross Profit history runs 11 years deep, the most recent figure standing at $244.5 million for Q1 2026.

• In Q1 2026, Gross Profit fell 78.98% year-over-year to $244.5 million; the TTM figure through Mar 2026 stood at $764.9 million (down 50.02% YoY), while the FY2025 annual figure was $1.7 billion, up 124.67% from the prior year.
• Gross Profit was $244.5 million for Q1 2026 at Ptc Therapeutics, up from $157.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $1.2 billion in Q1 2025 to a low of -$15.5 million in Q2 2024.
• Historically, Gross Profit has averaged $236.3 million across 5 years, with a median of $195.2 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Gross Profit sank 107.72% in 2024, then jumped 1178.48% in 2025.
• A 5-year view of Gross Profit shows it stood at $156.5 million in 2022, then jumped by 77.57% to $277.9 million in 2023, then declined by 29.16% to $196.9 million in 2024, then declined by 19.89% to $157.7 million in 2025, then soared by 55.03% to $244.5 million in 2026.
• The last three Gross Profit figures came in at $244.5 million (Q1 2026), $157.7 million (Q4 2025), and $195.2 million (Q3 2025), per Business Quant data.